Brief: Silo Pharma Advances Clinical Study Analyzing Effects Of Psilocybin On Inflammation
10/01/2023 21:46
Jan 10 (Reuters) - Silo Pharma Inc SILO.O :
* SILO PHARMA ADVANCES CLINICAL STUDY ANALYZING EFFECTS OF
PSILOCYBIN ON INFLAMMATION
* SILO PHARMA INC - RESEARCH TEAM IS ON TRACK TO COMPLETE
DATA
COLLECTION FROM PARKINSON'S DISEASE PATIENTS BY END OF FEBRUARY
2023
* SILO PHARMA INC - DATA COLLECTION IS EXPECTED TO BEGIN IN
EARLY
2023 FOR BIPOLAR STUDY, AND IN APRIL 2023 FOR CHRONIC PAIN STUDY
PATIENTS
Source text for Eikon: ID:nGNXXrH6W
Further company coverage: SILO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement